Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cTACE plus modified FOLFOX HAIC versus cTACE alone in intermediate-advanced hepatocellular carcinoma
ChiCTR1900026751Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid and ethiodized oil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: overall survival. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900026751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026751.